TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02509611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hatha yoga
Description: Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
Study: NCT00948428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara™
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study: NCT03425851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diapers
Description: Receive 600 diapers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resources of diaper banks
Description: Caregivers will receive resources of diaper banks.
Study: NCT04483128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation: Interferential Current (IFC): Experimental Group
Description: Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical stimulation: Interferential Current (IFC): Control Group
Description: Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes
Study: NCT02493335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5mg orodispersible tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1mg orodispersible tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orodispersible tablet twice daily
Study: NCT01783470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta3-adrenergic receptor agonist
Description: single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
Study: NCT00766064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline.
Study: NCT01237301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Group
Description: Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG Group
Description: Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
Study: NCT00093470

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study: NCT03367611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood test (iFOBT)
Description: All participants in the study will collect a single faecal sample for haemoglobin measurement.
Study: NCT00033592

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Study: NCT01606007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Tablets, Oral, 5mg , Once daily, 24 weeks
Study: NCT02168712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Study: NCT01606007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5mg , Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Study: NCT01770145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APOKYN
Description: Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
Study: NCT02063724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed Dendritic Cell Vaccine
Description: 6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
Study: NCT03309306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural Environment/Stress Management
Description: Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
Study: NCT01770145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethobenzamide
Description: Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
Study: NCT05942170

Intervention type: DRUG
Group type: OTHER
Intervention: ICG/ blue dye
Description: The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
Study: NCT02305550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical pulsed plasma discharge synthesis of nitric oxide
Description: An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
Study: NCT02676453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Dental hygienist support
Study: NCT03249701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: The intervention will be administered by electrical acupoint machine, the brand is Great Wall.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Description: The intervention will be administered by electrical acupoint machine, the brand is Great Wall.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcutaneous Electrical Acupoint Stimulation
Description: The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
Study: NCT00914238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 years OPUS treatment
Description: 2 years OPUS and transfer to standard treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPUS 5 years
Study: NCT05145673

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (OGTT)
Description: The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon (OGTT plus aqueous cinnamon extract)
Description: The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
Study: NCT03945448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose liposomal Amphotericin and Fluconazole
Description: Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
Study: NCT02668952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolyte S injection
Study: NCT04125303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivational psychoeducational therapy
Description: The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
Study: NCT01606007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10mg , Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10mg , Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Dapagliflozin
Description: Tablets, Oral, 0mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching with Saxagliptin
Description: Tablets, Oral, 0mg, Once daily, 24 weeks
Study: NCT03266965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
Study: NCT03953885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fire needle
Description: 1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fire needle Placebo
Description: 1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm.
Study: NCT02772224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon angioplasty
Description: In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balloon angioplasty
Description: The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
Study: NCT02637804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: contact lens
Study: NCT05872698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02798133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OLA
Description: PEEP titration trial for best Cdyn after the alveolar recruitment maneuver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM-5
Description: Fixed standard PEEP after the alveolar recruitment maneuver
Study: NCT03824613

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary miRNA
Description: MiRNA detection in urine
Study: NCT01374191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinum toxin type-A
Description: 1 injection of Btx-A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 injection of saline solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2nd phase - onabotulinum toxin type-A
Description: 2 - 3 injections of Btx-A, specific to patient pain recurrence
Study: NCT03634176

Intervention type: DIAGNOSTIC_TEST
Intervention: optical nerve sheet diameter
Description: The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).

Intervention type: DIAGNOSTIC_TEST
Intervention: optical nerve sheet diameter
Description: The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).

Intervention type: DIAGNOSTIC_TEST
Intervention: optical nerve sheet diameter
Description: The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
Study: NCT02325960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: ≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: ≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
Study: NCT01131754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heparin 100U/L flushes
Description: peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heparin 100U/L flushes
Description: peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
Study: NCT01949558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study: NCT01230632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat overfeeding
Description: Dietary Supplement:3 days overfeeding
Study: NCT06498492

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
Study: NCT02792972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A. oleracea
Description: The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 70% alcohol
Description: 70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.